NIH NIA Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
NIH NIMH Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
NIH NIMH Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
NIH NIMH NEI NIA NIAAA NIDCD NIDA NINDS BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)
NIH NIMH NEI NIA NIAAA NIDCD NIDA NINDS BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)
NIH NIMH Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
Alzheimer's Drug Discovery Foundation (ADDF) & Association for Frontotemporal Degeneration (AFTD) Accelerating Drug Discovery for Frontotemporal Degeneration
Fondation Maladies Rares Appel à candidatures 2026 ? Bourse de Master 2 ? « Innovation en Intelligence Artificielle & e-Santé pour les Maladies Rares »
